Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oogenesis02:07

Oogenesis

63.5K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.5K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

145
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
145

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epigenetic Changes in the Mature Uterus Following Neonatal Feeding of Tamoxifen in Female ICR Mice.

Reproductive medicine and biology·2026
Same author

A pilot study on the use of transcutaneous auricular vagus nerve stimulation to relieve dysmenorrhea in patients with adenomyosis and endometriosis.

Reproduction & fertility·2026
Same author

Exposure to Green Light-emitting Diodes Alleviates Endometriosis-associated Pain in Mice with Induced Deep Endometriosis.

Reproductive sciences (Thousand Oaks, Calif.)·2026
Same author

Impaired PIEZO1 function drives uterine hypercontractility in adenomyosis-associated dysmenorrhea.

Human reproduction open·2026
Same author

Cracking the enigma of adenomyosis: prospects and challenges.

Nature reviews. Endocrinology·2025
Same author

Reduced vagal tone in women with adenomyosis.

Reproduction & fertility·2025

Related Experiment Video

Updated: Jun 14, 2025

A Syngeneic Murine Model of Endometriosis using Naturally Cycling Mice
07:12

A Syngeneic Murine Model of Endometriosis using Naturally Cycling Mice

Published on: November 24, 2020

5.1K

Drug development for adenomyosis based on pathophysiology.

Sun-Wei Guo1

  • 1Shanghai Obstetrics and Gynecology Hospital, Fudan University and Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Fudan University, Shanghai, China.

The Journal of Obstetrics and Gynaecology Research
|June 12, 2025
PubMed
Summary

Developing non-hormonal drugs for adenomyosis faces significant challenges, with current trials showing limited success. Future research will focus on a deeper understanding of adenomyosis pathophysiology to identify new therapeutic targets.

Keywords:
adenomyosisanimal modelclinical trialsdrug developmentpathophysiology

More Related Videos

Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis
08:16

Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis

Published on: February 26, 2019

8.1K
Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development
07:56

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

16.5K

Related Experiment Videos

Last Updated: Jun 14, 2025

A Syngeneic Murine Model of Endometriosis using Naturally Cycling Mice
07:12

A Syngeneic Murine Model of Endometriosis using Naturally Cycling Mice

Published on: November 24, 2020

5.1K
Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis
08:16

Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis

Published on: February 26, 2019

8.1K
Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development
07:56

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

16.5K

Area of Science:

  • Gynecology
  • Pharmacology
  • Pathophysiology

Background:

  • Adenomyosis is a prevalent uterine condition requiring medical intervention.
  • Currently, no drugs are exclusively developed for adenomyosis treatment.
  • Non-hormonal drug development for adenomyosis has historically been unsuccessful.

Purpose of the Study:

  • To outline challenges in developing non-hormonal drugs for adenomyosis.
  • To provide an overview of adenomyosis pathophysiology.
  • To identify promising avenues for future drug development.

Main Methods:

  • Review of published studies on adenomyosis.
  • Examination of clinical trials for adenomyosis registered at ClinicalTrials.gov.

Main Results:

  • Clinical trials for new adenomyosis drugs have yielded largely unsuccessful outcomes.
  • Limited efficacy was observed with aromatase inhibitors, oxytocin receptor antagonists, and dopamine receptor D2 agonists.
  • Mifepristone is the only reported efficacious drug, inducing amenorrhea.
  • A new mouse model for adenomyosis has been developed, aiding research into disease mechanisms and heavy menstrual bleeding.

Conclusions:

  • Enhanced understanding of adenomyosis pathophysiology is crucial.
  • Further research into disease mechanisms will uncover new druggable targets for adenomyosis treatment.